2021年1月21日 · The IsoPSA test is a novel prostate-specific antigen assay for patients with a PSA > 4ng/ml who are facing a decision on prostate biopsy. Listen as Dr. Klein discusses how the IsoPSA test differs from conventional PSA testing and how your patients can benefit.

IsoPSA® - IsoPSA is a structure-based (rather than concentration- based) assay that interrogates the entire spectrum of structural changes to PSA (or isoforms), and can effectively differentiate between high-grade prostate cancer and lowgrade prostate cancer/benign.

IsoPSA is a blood test for men with elevated total PSA ≥ 4ng/mL that identifies structural differences in PSA proteins that are expressed by cancer. IsoPSA can clarify prostate cancer risk, enabling better biopsy decisions for patients who are either biopsy naïve or who have had prior negative biopsy.

2022年5月9日 · The results showed that in men with total PSA ≥4 ng/ml, IsoPSA led to a 55% (284 vs 638) net reduction in prostate biopsy recommendations. Further, there was also a 9% reduction in MRI imaging recommendations.

2021年12月14日 · The difference between conventional PSA and the new IsoPSA test has to do with the 3-dimensional molecular form of the PSA protein molecules. A traditional PSA test is a simple count, whereas the IsoPSA can define the distinctive 3-D structure of …

2024年6月23日 · IsoPSA is a blood test that's indicated for men over 50 years old with a PSA greater than 4 ng/mL. It's meant to be an adjuvant marker for an abnormal PSA. IsoPSA does not simply measure PSA concentration, but it's looking at different isoforms of PSA.

2020年7月7日 · Designed to stratify risk of biologically significant prostate cancer (Gleason grade > 7 prostate cancer), IsoPSA is intended to be used in men who are age 50 and older with a total PSA > 4 ng/ml with no previous prostate cancer diagnosis and not under active surveillance.